Consainsights logo
  • Reports /
  • Rare Disease Genetic Testing Market

Rare Disease Genetic Testing Market

Rare Disease Genetic Testing Market Market Research Report – Segmented By Technology (Next-generation Sequencing, Array Technology, PCR-based Testing, FISH, Other Technologies), By Disease (Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine and Metabolism Diseases, Cancer, Musculoskeletal Disorders, Other Diseases), By End User (Clinics/Hospitals, Diagnostic Laboratories, Other End Users) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.

Table of contents

Executive Summary

Rare Disease Genetic Testing Market from Consainsights analyses the Rare Disease Genetic Testing Market Market in the Life Sciences industry over the forecast period to 2027.

Figure 1: Rare Disease Genetic Testing Market Size, 2019-2027

Rare Disease Genetic Testing Market research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Rare Disease Genetic Testing Market segmentation includes Technology, Disease, End User and Geography.

All segmentations encompasses the key innovations and micro & macro trends, companies/manufacturers operating in this space along with their usage and penetration with respect to the wide range of End Users. Additionally, market sizing information along with the key factors such as market drivers, restraints, opportunities and challenges which are likely to be influencing the market growth are outlined in this report.

Based on the Technology, the Rare Disease Genetic Testing Market analysis covers Next-generation Sequencing, Array Technology, PCR-based Testing, FISH, Other Technologies.

Figure 2: Rare Disease Genetic Testing Market Share (%), Technology 2021

Based on the Disease, the Rare Disease Genetic Testing Market analysis covers Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine and Metabolism Diseases, Cancer, Musculoskeletal Disorders, Other Diseases.

Figure 3: Rare Disease Genetic Testing Market Share (%), Disease 2021

Based on the End User, the Rare Disease Genetic Testing Market analysis covers Clinics/Hospitals, Diagnostic Laboratories, Other End Users.

Figure 4: Rare Disease Genetic Testing Market Share (%), End User 2021

Key companies operating in the market include Quest Diagnostics Incorporated, Centogene NV, Invitae Corporation, 3billion Inc., ARUP Laboratories, Eurofins Scientific, Strand Life Sciences, Ambry Genetics, PerkinElmer Genetics Inc., Macrogen Inc., Baylor Genetics, Color Health Inc., Health Network Laboratories and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Moreover, the competitive analysis includes the companies deals such as Mergers, Acquisitions, Partnerships and so on along with the expansion areas focusing on the additional geographies, future insights for success and market share analysis. Major players strategies include the launch of the innovative product lines along with the emphasis on the partnerships and acquisitions to standardize their market share in the market space.

Market Research methodology includes the triangulation of the data from the data sources such as Primary Market Research approach and Secondary Market Research Approach along with the data from the trade bodies and industry standard publications and data sources. Primary inputs from the industry experts and the market respondents from the respective industries to obtain very critical information to assess the future growth prospects of the market. The final data is triangulated and thoroughly validated considering all the data sources using the bottom-up and the top-down approaches to estimate the market sizing of the individual segments.

Market Overview

Definition & Scope

  • The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
  • The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
  • The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
  • Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
  • Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
  • As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

By Technology

Introduction

By By Technology, The Rare Disease Genetic Testing Market analysis covers Next-generation Sequencing, Array Technology, PCR-based Testing, FISH, Other Technologies.

Table: 1: Rare Disease Genetic Testing Market Size, By By Technology

Next-generation Sequencing

The Next-generation Sequencing segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Array Technology

The Array Technology segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

PCR-based Testing

The PCR-based Testing segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

FISH

The FISH segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other Technologies

The Other Technologies segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

By Disease

Introduction

By By Disease, The Rare Disease Genetic Testing Market analysis covers Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine and Metabolism Diseases, Cancer, Musculoskeletal Disorders, Other Diseases.

Table: 2: Rare Disease Genetic Testing Market Size, By By Disease

Neurological Disorders

The Neurological Disorders segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Immunological Disorders

The Immunological Disorders segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Hematology Diseases

The Hematology Diseases segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Endocrine and Metabolism Diseases

The Endocrine and Metabolism Diseases segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Cancer

The Cancer segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Musculoskeletal Disorders

The Musculoskeletal Disorders segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other Diseases

The Other Diseases segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

By End User

Introduction

By By End User, The Rare Disease Genetic Testing Market analysis covers Clinics/Hospitals, Diagnostic Laboratories, Other End Users.

Table: 3: Rare Disease Genetic Testing Market Size, By By End User

Clinics/Hospitals

The Clinics/Hospitals segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Diagnostic Laboratories

The Diagnostic Laboratories segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other End Users

The Other End Users segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Company Analysis

Introduction

Key companies operating in the market include Quest Diagnostics Incorporated, Centogene NV, Invitae Corporation, 3billion Inc., ARUP Laboratories, Eurofins Scientific, Strand Life Sciences, Ambry Genetics, PerkinElmer Genetics Inc., Macrogen Inc., Baylor Genetics, Color Health Inc., Health Network Laboratories and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.